Polyethylenimine: An Intranasal Adjuvant for Liposomal Peptide-Based Subunit Vaccine against Group A <i>Streptococcus</i>

Dai, Charles C; Yang, Jieru; Hussein, Waleed M.; Zhao, Lili; Wang, Xiumin; Khalil, Zeinab; Capon, Robert J.; Tóth, István; Stephenson, Rachel J.

doi:10.1021/acsinfecdis.0c00452

Cited by 24 publications

(21 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, some polymer, such as polyethylenimine (PEI), which could attach to the cells’ surface and deliver cargo into endosomal and cytosolic compartments, was introduced in the lipopeptide-based vaccine design. PEI incorporated in liposome peptide vaccine could induce significant specific mucosal and systemic antibodies, which effectively opsonize multiple isolates of clinically isolated GAS ( 407 ). Further, they found that the ratio of PEI, rather than molecular weight, present in the liposome vaccines impact immune response ( 408 ).…”

Section: Protein-based Bacterial Vaccine Delivery Systemmentioning

confidence: 99%

Peptide-Based Vaccines for Tuberculosis

Gong

Pan²,

Cheng

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis. As a result of the coronavirus disease 2019 (COVID-19) pandemic, the global TB mortality rate in 2020 is rising, making TB prevention and control more challenging. Vaccination has been considered the best approach to reduce the TB burden. Unfortunately, BCG, the only TB vaccine currently approved for use, offers some protection against childhood TB but is less effective in adults. Therefore, it is urgent to develop new TB vaccines that are more effective than BCG. Accumulating data indicated that peptides or epitopes play essential roles in bridging innate and adaptive immunity and triggering adaptive immunity. Furthermore, innovations in bioinformatics, immunoinformatics, synthetic technologies, new materials, and transgenic animal models have put wings on the research of peptide-based vaccines for TB. Hence, this review seeks to give an overview of current tools that can be used to design a peptide-based vaccine, the research status of peptide-based vaccines for TB, protein-based bacterial vaccine delivery systems, and animal models for the peptide-based vaccines. These explorations will provide approaches and strategies for developing safer and more effective peptide-based vaccines and contribute to achieving the WHO’s End TB Strategy.

show abstract

Section: Protein-based Bacterial Vaccine Delivery Systemmentioning

confidence: 99%

Peptide-Based Vaccines for Tuberculosis

Gong

Pan²,

Cheng

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Furthermore, the use of PEI to control CpG release presents an additional consideration, as PEI has been used as a vaccine adjuvant capable of improving DC antigen presentation, mixed-Th1/Th2 responses, and IgG antibody titers. [18,[47][48][49] PEI has also been shown to stimulate type-2 immunity and secretion of IL-5 and IL-10, among other cytokines. [49][50][51] These reports are broadly consistent with our finding that PLG scaffolds containing GM-CSF, OVA, and PEI alone (without CpG) induced an IL-5, Th2-biased response (Figure 2f,g).…”

Section: Discussionmentioning

confidence: 99%

Scaffold Vaccines for Generating Robust and Tunable Antibody Responses

Najibi

Dellacherie

Shih

et al. 2022

Adv Funct Materials

View full text Add to dashboard Cite

Traditional bolus vaccines often fail to sustain robust adaptive immune responses, typically requiring multiple booster shots for optimal efficacy. Additionally, these provide few opportunities to control the resulting subclasses of antibodies produced, which can mediate effector functions relevant to distinct disease settings. Here, it is found that three scaffold-based vaccines, fabricated from poly(lactide-co-glycolide) (PLG), mesoporous silica rods, and alginate cryogels, induce robust, long-term antibody responses to a model peptide antigen gonadotropin-releasing hormone with single-shot immunization. Compared to a bolus vaccine, PLG vaccines prolong germinal center formation and T follicular helper cell responses. Altering the presentation and release of the adjuvant (cytosine-guanosine oligodeoxynucleotide, CpG) tunes the resulting IgG subclasses. Further, PLG vaccines elicit strong humoral responses against disease-associated antigens HER2 peptide and pathogenic E. coli, protecting mice against E. coli challenge more effectively than a bolus vaccine. Scaffold-based vaccines may thus enable potent, durable and versatile humoral immune responses against disease.

show abstract

“…The particle size distribution of the malaria vaccine components was measured using a laser particle analyser (Zeta sizer 2000E, Malvern Instruments Ltd., Malvern, UK). The emulsion was diluted 10 times, then transferred to disposable zeta sizer cuvettes before measurement at 25˚C with a 173˚light scattering angle [27].…”

Section: Particle Size Analysismentioning

confidence: 99%

Investigation of liposomal self-adjuvanting peptide epitopes derived from conserved blood-stage Plasmodium antigens

Islam

Nahar

et al. 2022

PLoS ONE

Self Cite

View full text Add to dashboard Cite

Malaria is a vector born parasitic disease causing millions of deaths every year. Despite the high mortality rate, an effective vaccine against this mosquito-borne infectious disease is yet to be developed. Up to date, RTS,S/AS01 is the only vaccine available for malaria prevention; however, its efficacy is low. Among a variety of malaria antigens, merozoite surface protein-1(MSP-1) and ring-infected erythrocyte surface antigen (RESA) have been proposed as promising candidates for malaria vaccine development. We developed peptide-based Plasmodium falciparum vaccine candidates that incorporated three previously reported conserved epitopes from MSP-1 and RESA into highly effective liposomal polyleucine delivery system. Indeed, MSP-1 and RESA-derived epitopes conjugated to polyleucine and formulated into liposomes induced higher epitope specific antibody titres. However, immunized mice failed to demonstrate protection in a rodent malaria challenge study with Plasmodium yoelii. In addition, we found that the three reported P. falciparum epitopes did not to share conformational properties and high sequence similarity with P. yoelii MSP-1 and RESA proteins, despite the epitopes were reported to protect mice against P. yoelii challenge.

show abstract

Polyethylenimine: An Intranasal Adjuvant for Liposomal Peptide-Based Subunit Vaccine against Group A Streptococcus

Cited by 24 publications

References 46 publications

Peptide-Based Vaccines for Tuberculosis

Peptide-Based Vaccines for Tuberculosis

Scaffold Vaccines for Generating Robust and Tunable Antibody Responses

Investigation of liposomal self-adjuvanting peptide epitopes derived from conserved blood-stage Plasmodium antigens

Contact Info

Product

Resources

About